Updates on the management of breast cancer brain metastases.
Updates on the management of breast cancer brain metastases.
复制标题
作者：
E. Lim;N. Lin
乳腺癌脑转移（BCBM）在晚期疾病患者中很常见。乳腺癌亚型和表现状态是脑转移诊断后病程和生存时间的主要决定因素。 BCBM 管理所面临的独特挑战包括克服血脑屏障和对传统全身疗法的耐药性，因为 BCBM 通常发生在接受过治疗的患者群体中。新的乳腺癌全身疗法的开发，加上试验设计、成像方式以及定义和测量临床终点的方法的改进，引起了人们对开发新的 BCBM 治疗方法的新兴趣。在本概述中，我们将回顾 BCBM 管理的最新进展以及当前专门针对 BCBM 患者的全身疗法的前瞻性试验，重点是新型途径特异性疗法。
Breast cancer brain metastases (BCBMs) are common in patients with advanced disease. Breast cancer subtype and performance status are the major determinants of the course of the disease and survival time following a diagnosis of brain metastasis. Unique challenges specific to the management of BCBMs include overcoming the blood-brain barrier and resistance to conventional systemic therapies, as BCBMs typically occur in the pretreated patient population. The development of new systemic therapies for breast cancer, coupled with improvements in trial design, imaging modalities, and methods of defining and measuring clinical endpoints, has led to a renewed interest in developing novel therapeutic approaches for BCBMs. In this overview, we will review recent developments in the management of BCBMs and current prospective trials of systemic therapies specifically for patients with BCBMs, with a focus on novel pathway-specific therapies.